GlassScriptPhysician profile
Bryon K Evans
NPI 1942280011
$211,356.81
in general payments reported to CMS, 2019-2025
42 companies · $123K in 2025
The $123K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,580 · 2020: $5,882 · 2021: $4,461 · 2022: $7,485 · 2023: $22K · 2024: $46K · 2025: $123K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $114K · Honoraria: $43K · Food and Beverage: $16K · Travel and Lodging: $13K · Consulting Fee: $5,500 · Education: $5.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $113,752.25 |
| Honoraria | $43,450.00 |
| Food and Beverage | $15,740.54 |
| Travel and Lodging | $13,499.75 |
| Consulting Fee | $5,500.00 |
| Education | $5.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $87,788.13 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $65,603.08 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31,627.07 | 2020-2025 | Caplyta |
| Alkermes, INC. | $8,137.95 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $6,206.68 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Neurocrine Biosciences, INC. | $1,396.90 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $1,138.81 | 2019-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $1,101.77 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $992.68 | 2019-2025 | Trintellix |
| Corium, LLC | $819.66 | 2021-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $779.66 | 2020-2025 | Fanapt |
| Neos Therapeutics, LP | $770.59 | 2020-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt, Exxua |
| Abbvie INC. | $683.94 | 2022-2025 | |
| Noven Therapeutics, LLC | $653.90 | 2020-2025 | Xelstrym, Secuado |
| Axsome Therapeutics, INC. | $543.04 | 2023-2025 | Auvelity |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $369.45 | 2022-2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $362.60 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $309.70 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $296.05 | 2022-2025 | Dyanavel Xr |
| Galt Pharmaceuticals, LLC | $211.20 | 2023 | Orphengesic Forte |
| Idorsia Pharmaceuticals US INC | $167.97 | 2022-2025 | Quviviq, Quviviq |
| Almatica Pharma LLC | $162.32 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Shire North American Group INC | $135.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $133.12 | 2024-2025 | Cobenfy |
| Brainsway USA INC | $119.88 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $108.09 | 2025 | Jornay Pm |
| Aytu Biopharma, INC. | $106.64 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $91.60 | 2019-2025 | Relexxii |
| Avanir Pharmaceuticals, INC. | $76.52 | 2019-2022 | |
| Avion Pharmaceuticals | $73.79 | 2023 | Methylphenidate Hydrochloride |
| Adlon Therapeutics L.P. | $68.84 | 2020-2021 | |
| Luye Pharma (USA) LTD. | $63.27 | 2025 | Erzofri Extended-Release |
| Merck Sharp & Dohme LLC | $42.71 | 2022-2023 | Belsomra |
| Bausch Health US, LLC | $41.46 | 2024-2025 | Aplenzin, Wellbutrin |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.85 | 2024-2025 | Abilify Maintena |
| Tempus Ai, INC | $28.19 | 2024 | |
| Lilly USA, LLC | $22.81 | 2025 | Zepbound |
| Owp Pharmaceuticals, INC. | $21.82 | 2025 | Subvenite |
| Sage Therapeutics, LLC | $21.29 | 2019 | |
| Neuronetics, INC. | $15.23 | 2025 | Neurostar Tms Therapy System |
| Eisai INC. | $14.88 | 2020 | |
| Biogen, INC. | $14.55 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryon Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.